Aethlon Medical Reports Consistent Biomarker Changes in Second Cohort of Oncology Trial
Event summary
- Aethlon Medical observed directional biomarker changes in the second cohort of its Australian oncology feasibility study, consistent with first-cohort results.
- The study evaluates the Hemopurifier® in advanced solid tumor patients unresponsive to anti-PD-1 immunotherapies.
- Key findings include reductions in tumor-derived extracellular vesicles (EVs) and improvements in immune-related laboratory ratios.
- Enrollment in the third cohort is underway, with an independent statistical analysis planned post-completion.
The big picture
Aethlon Medical's consistent biomarker findings across two cohorts strengthen the scientific rationale for its Hemopurifier®, a device designed to remove tumor-derived extracellular vesicles. The results support the growing recognition of EVs as drivers of cancer progression and resistance to checkpoint inhibitors. If replicated in the third cohort, these observations could position Aethlon as a key player in the evolving landscape of cancer immunotherapy.
What we're watching
- Clinical Validation
- Whether the observed biomarker changes will translate into meaningful clinical outcomes in subsequent trials.
- Regulatory Pathway
- The pace at which Aethlon can advance the Hemopurifier through FDA Breakthrough Device Designation.
- Market Positioning
- How Aethlon positions the Hemopurifier as a complementary therapy alongside existing cancer treatments like Keytruda and Opdivo.
Related topics